Payment overview · 2025
General Payments
$436.38
22 reported records · 7 companies
Healthcare provider profile · identity verified
Luis Alberto Martinez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DORAL, FL · NPI 1972605533
Verified facts
What the public records show
CMS Open Payments records show Luis Alberto Martinez, MD received $436.38 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca UK Limited reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 30 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.61 | 32.9% | 11 | 2025 |
| AstraZeneca UK Limited | Unresolved — no canonical attribution shown | $135.00 | 30.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.38 | 15.4% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.64 | 5.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.08 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.50 | 5.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.17 | 4.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $436.38 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $143.61 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.74 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.24 | 2 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.17 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| AstraZeneca UK Limited Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 30 supporting records · 16 recipient NPIs · example record 1202913210 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 67 |
| Omeprazole | Omeprazole | 322 | 80 |
| Lactulose | Lactulose | 294 | 31 |
| Simvastatin | Simvastatin | 279 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 278 | 71 |
| Lisinopril | Lisinopril | 248 | 63 |
| Famotidine | Famotidine | 240 | 45 |
| Alendronate Sodium | Alendronate Sodium | 218 | 34 |
| Losartan Potassium | Losartan Potassium | 205 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 40 |
| Metformin Hcl | Metformin Hcl | 195 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 88 |
| Lorazepam | Lorazepam | 109 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 39 |
| Azelastine Hcl | Azelastine Hcl | 102 | 86 |
| Gabapentin | Gabapentin | 96 | 35 |
| Levetiracetam | Levetiracetam | 92 | 11 |
| Montelukast Sodium | Montelukast Sodium | 91 | 15 |
| Levocarnitine | Levocarnitine (With Sugar) | 85 | suppressed |
| Furosemide | Furosemide | 84 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 20 |
| Carbamazepine | Carbamazepine | 63 | suppressed |
| Carvedilol | Carvedilol | 62 | 14 |
| Linzess | Linaclotide | 62 | 15 |
| Glipizide | Glipizide | 59 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 57 | 37 |
| Eliquis | Apixaban | 55 | 11 |
| Topiramate | Topiramate | 55 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 55 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 31 |
| Baclofen | Baclofen | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 39 |
| Ammonium Lactate | Ammonium Lactate | 49 | 20 |
| Cefdinir | Cefdinir | 48 | 38 |
| Ozempic | Semaglutide | 47 | 16 |
| Vascepa | Icosapent Ethyl | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Finasteride | Finasteride | 43 | suppressed |
| Potassium Chloride | Potassium Chloride | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | 11 |
| Trazodone Hcl | Trazodone Hcl | 40 | 21 |
| Mupirocin | Mupirocin | 39 | 25 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 38 | 11 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 23 |
| Lacosamide | Lacosamide | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 31 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 33 | 18 |
| Ketoconazole | Ketoconazole | 32 | 18 |
| Atenolol | Atenolol | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Nystatin | Nystatin | 26 | 16 |
| Clotrimazole | Clotrimazole | 25 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 13 |
| Alprazolam | Alprazolam | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Levofloxacin | Levofloxacin | 21 | 12 |
| Metronidazole | Metronidazole | 21 | 14 |
| Digoxin | Digoxin | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Prolia | Denosumab | 20 | 12 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Unithroid | Levothyroxine Sodium | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $436.38 · 22 records | Amgen Inc. | Cologuard Collection Kit, JARDIANCE, LEQVIO, NURTEC ODT, OTEZLA, PAXLOVID, REPATHA, VPRIV | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error